Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Multiple Sclerosis

  Free Subscription


22.03.2021

1 BMC Neurol
3 J Immunol
1 J Neuroimmunol
2 J Neurol
2 J Neurol Neurosurg Psychiatry
1 J Neurol Sci
8 Mult Scler
2 Neurologia
1 Neurology


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    BMC Neurol

  1. SAUDER T, Keune PM, Muller R, Schenk T, et al
    Trait mindfulness is primarily associated with depression and not with fatigue in multiple sclerosis (MS): implications for mindfulness-based interventions.
    BMC Neurol. 2021;21:115.
    PubMed         Abstract available


    J Immunol

  2. LI Z, He C, Zhang J, Zhang H, et al
    P2Y6 Deficiency Enhances Dendritic Cell-Mediated Th1/Th17 Differentiation and Aggravates Experimental Autoimmune Encephalomyelitis.
    J Immunol. 2020 Jun 17. pii: jimmunol.1900916. doi: 10.4049/jimmunol.1900916.
    PubMed         Abstract available

  3. CLARKE J, Yaqubi M, Futhey NC, Sedaghat S, et al
    Vitamin D Regulates MerTK-Dependent Phagocytosis in Human Myeloid Cells.
    J Immunol. 2020;205:398-406.
    PubMed         Abstract available

  4. BOYDEN AW, Brate AA, Stephens LM, Karandikar NJ, et al
    Immune Autoregulatory CD8 T Cells Require IFN-gamma Responsiveness to Optimally Suppress Central Nervous System Autoimmunity.
    J Immunol. 2020 Jun 12. pii: jimmunol.2000211. doi: 10.4049/jimmunol.2000211.
    PubMed         Abstract available


    J Neuroimmunol

  5. GIARRAPUTO J, Giamberardino S, Arvai S, Maichle S, et al
    Profiling serum neurofilament light chain and glial fibrillary acidic protein in primary progressive multiple sclerosis.
    J Neuroimmunol. 2021;354:577541.
    PubMed         Abstract available


    J Neurol

  6. PATTI F, Zimatore GB, Brescia Morra V, Aguglia U, et al
    Administration of subcutaneous interferon beta 1a in the evening: data from RELIEF study.
    J Neurol. 2020;267:1812-1823.
    PubMed         Abstract available

  7. CAROTENUTO A, Costabile T, De Lucia M, Moccia M, et al
    Predictors of Nabiximols (Sativex((R))) discontinuation over long-term follow-up: a real-life study.
    J Neurol. 2020;267:1737-1743.
    PubMed         Abstract available


    J Neurol Neurosurg Psychiatry

  8. KEIR LHM, Breen DP
    REM sleep behaviour disorder in patients without synucleinopathy.
    J Neurol Neurosurg Psychiatry. 2020;91:1239-1240.
    PubMed        

  9. PFEUFFER S, Ruck T, Pul R, Rolfes L, et al
    Impact of previous disease-modifying treatment on effectiveness and safety outcomes, among patients with multiple sclerosis treated with alemtuzumab.
    J Neurol Neurosurg Psychiatry. 2021 Mar 12. pii: jnnp-2020-325304.
    PubMed         Abstract available


    J Neurol Sci

  10. RINI AM, Clerici VT, Rinaldi E, Modesto M, et al
    Severe thrombocytopenia during Natalizumab therapy: A case report.
    J Neurol Sci. 2020;409:116587.
    PubMed        


    Mult Scler

  11. CHIARAVALLOTI ND, Moore NB, DeLuca J
    The efficacy of the modified Story Memory Technique in progressive MS.
    Mult Scler. 2020;26:354-362.
    PubMed         Abstract available

  12. MEYER CE, Gao JL, Cheng JY, Oberoi MR, et al
    Axonal damage in spinal cord is associated with gray matter atrophy in sensorimotor cortex in experimental autoimmune encephalomyelitis.
    Mult Scler. 2019 Mar 7:1352458519830614. doi: 10.1177/1352458519830614.
    PubMed         Abstract available

  13. DURAND-DUBIEF F, Marignier R, Berthezene Y, Cottin J, et al
    Spontaneous multiple cervical artery dissections after alemtuzumab.
    Mult Scler. 2020;26:381-383.
    PubMed         Abstract available

  14. COBO-CALVO A, Marignier R
    MOG-antibody-associated disease is different from MS and NMO and should be considered as a distinct disease entity - No.
    Mult Scler. 2020;26:274-276.
    PubMed        

  15. LEITE MI, Sato DK
    MOG-antibody-associated disease is different from MS and NMOSD and should be considered as a distinct disease entity - Yes.
    Mult Scler. 2020;26:272-274.
    PubMed        

  16. YEH EA
    Real-world outcomes in pediatric MS: Psychiatric comorbidities and school performance.
    Mult Scler. 2021;27:165-166.
    PubMed        

  17. BRIGGS FB, Krill D, Hill E, Conway DS, et al
    Age of hypertension onset in multiple sclerosis patients.
    Mult Scler. 2021 Mar 18:13524585211003016. doi: 10.1177/13524585211003016.
    PubMed         Abstract available

  18. BESSING B, Honan CA, van der Mei I, Taylor BV, et al
    Development and psychometric properties of the Multiple Sclerosis Knowledge Assessment Scale: Rasch analysis of a novel tool for evaluating MS knowledge.
    Mult Scler. 2021;27:767-777.
    PubMed         Abstract available


    Neurologia

  19. ALBA SUAREZ EM, Tallon Barranco A, Puertas Munoz I, Chamorro Hernandez B, et al
    Non-late-onset neutropaenia following treatment of multiple sclerosis with ocrelizumab.
    Neurologia. 2021 Mar 13. pii: S0213-4853(21)00026.
    PubMed         Abstract available

  20. SANCHEZ-SOBLECHERO A, Cuello JP, Martinez Gines ML, Lozano Ros A, et al
    Recurrent intracranial hemorrhage in a patient with relapsing multiple sclerosis under interferon-beta therapy.
    Neurologia. 2021 Mar 12. pii: S0213-4853(21)00011.
    PubMed        


    Neurology

  21. POIRION E, Tonietto M, Lejeune FX, Ricigliano VAG, et al
    Structural and Clinical Correlates of a Periventricular Gradient of Neuroinflammation in Multiple Sclerosis.
    Neurology. 2021 Mar 18. pii: WNL.0000000000011700.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Multiple Sclerosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: